Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
CATX
Perspective Therapeutics, Inc.
Company directly develops and provides radiopharmaceuticals using alpha-emitting Lead-212 for targeted cancer therapy and diagnostic imaging via 203Pb in a theranostic approach.
|
$165.61M |
$2.25
+2.51%
|
|
NTHI
NEONC TECHNOLOGIES HOLDINGS, INC.
Directly produces oncology-focused biotech therapies; lead programs NEO100/NEO212 targeting brain cancers.
|
$164.29M |
$8.71
-1.47%
|
|
SAVA
Cassava Sciences, Inc.
Direct product category: simufilam is developed as an oral small-molecule therapeutic.
|
$163.76M |
$3.40
+11.68%
|
|
CNTB
Connect Biopharma Holdings Limited
Lead asset CBP-201 (rademikibart) is a monoclonal antibody targeting IL-4Rα, directly fitting Monoclonal Antibody Therapeutics.
|
$157.69M |
$2.87
+3.24%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$157.07M |
$1.75
+3.87%
|
|
THTX
Theratechnologies Inc.
EGRIFTA WR and TH1902 are peptide-based therapeutics, representing Theratechnologies' core peptide therapeutics business.
|
$155.87M |
$3.39
|
|
CRDF
Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company focused on oncology therapeutics, with its lead asset targeting cancer (onvansertib).
|
$155.67M |
$2.33
+10.66%
|
|
NVCT
Nuvectis Pharma, Inc.
Nuvectis' lead asset NXP900 is a cancer-targeting therapy (SRC/YES1 kinase inhibitor), placing the company in Biotech - Oncology.
|
$154.27M |
$6.07
-0.41%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is an oncology-focused therapeutic developed by SELLAS, targeting cancer antigens (WT1) and used as an immunotherapy.
|
$153.73M |
$1.46
+1.04%
|
|
IPHA
Innate Pharma S.A.
Innate Pharma focuses on oncology therapies, including antibody-based approaches, making Biotech - Oncology a core business area.
|
$153.03M |
$1.88
+1.08%
|
|
SLSN
Solesence, Inc. Common Stock
Solésence operates as a contract development and manufacturing organization (CDMO) for beauty products, matching Contract Manufacturing Organizations.
|
$152.95M |
$2.22
-1.33%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$152.26M |
$1.31
+2.34%
|
|
ELTX
Elicio Therapeutics, Inc.
Lead product candidate is a cancer vaccine/immunotherapy, aligning with Vaccines.
|
$149.66M |
$9.15
+2.23%
|
|
ANIX
Anixa Biosciences, Inc.
CER-T CAR-T therapy is a direct cell therapy product focused on oncology.
|
$149.46M |
$4.64
+7.52%
|
|
MCRB
Seres Therapeutics, Inc.
SER-155 is a cultivated live biotherapeutic product (cell therapy) comprising a defined bacterial consortium.
|
$147.69M |
$16.93
+0.03%
|
|
PLX
Protalix BioTherapeutics, Inc.
Protalix manufactures recombinant proteins/enzymes (e.g., Elelyso, Elfabrio) using its plant-based ProCellEx system.
|
$145.91M |
$1.83
+2.51%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Corbus's pipeline is focused on oncology assets (CRB-701 and CRB-601) representing biotech oncology products.
|
$145.59M |
$11.90
+4.71%
|
|
AGEN
Agenus Inc.
Agenus' core focus is oncology with immunotherapy approaches (BOT/BAL) in MSS CRC, supporting Biotech - Oncology.
|
$144.98M |
$4.57
+4.34%
|
|
ACTU
Actuate Therapeutics Inc
Actuate Therapeutics is a biotech company focused on oncology with a lead product elraglusib (a GSK-3β inhibitor).
|
$143.14M |
$6.89
+10.24%
|
|
CGEN
Compugen Ltd.
Company focus and programs are centered in oncology/immuno-oncology, qualifying under Biotech - Oncology.
|
$142.36M |
$1.59
|
|
SCLX
Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
|
$141.48M |
$20.23
-0.12%
|
|
ANIK
Anika Therapeutics, Inc.
Non-opioid pain management solutions through HA injections address OA pain.
|
$141.01M |
$9.80
-1.80%
|
|
SRZN
Surrozen, Inc.
Direct ophthalmic drug development focusing on retinal diseases using Wnt-modulating antibodies.
|
$140.94M |
$16.46
+2.84%
|
|
SGMO
Sangamo Therapeutics, Inc.
Core platform enabling genomic medicine via gene therapy and genome regulation (ZF/ZFR) technology.
|
$140.02M |
$0.46
+10.84%
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$139.29M |
$4.56
-2.77%
|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 is Relmada's lead oncology candidate targeting non-muscle invasive bladder cancer (NMIBC).
|
$139.07M |
$4.18
-1.88%
|
|
MRSN
Mersana Therapeutics, Inc.
Mersana is an oncology-focused biotechnology company with Emi-Le and XMT-2056 in clinical development.
|
$137.44M |
$27.63
+0.82%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$136.64M |
$1.34
+5.08%
|
|
MOLN
Molecular Partners AG
Core focus on oncology therapeutics built on the DARPin platform.
|
$136.10M |
N/A
|
Showing page 15 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
